Risperidone in idiopathic and symptomatic dystonia: preliminary experience.
Risperidone is a heterocyclic neuroleptic with prominent antiserotoninergic (5HT2) as well as antidopaminergic (D2) activity. We studied the efficacy of risperidone in the treatment of idiopathic and symptomatic dystonias in seven patients using the Fahn and Marsden rating scale for torsion dystonia before and after four weeks of treatment (2-6 mg/day). The twisting and involuntary movements with abnormal postures decreased in all the patients treated, with a statistically significant mean improvement (41%; p = 0.009, CI 95%). Our results suggest that risperidone is useful in idiopathic and symptomatic dystonia.
Department of Neurological and Psychiatric Sciences, University of Florence, Italy.
E
E
Grassi
S
S
Latorraca
S
S
Piacentini
P
P
Marini
S
S
Sorbi
D000293:Adolescent; D000328:Adult; D018492:Dopamine Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D004421:Dystonia / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006993:Hypnotics and Sedatives; D008297:Male; D008875:Middle Aged; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D016896:Treatment Outcome
D018492:Dopamine Antagonists; D006993:Hypnotics and Sedatives; D012702:Serotonin Antagonists; D018967:Risperidone